Accès ouvert déclaré
2023
article
Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care
Mario Luca Morieri, Riccardo Candido, Simona Frontoni, Olga Disoteo, Anna Solini, Gian Paolo Fadini, Francesco Bellanti, Massimiliano Caprio, Michele Cutolo, Gloria Formoso, Elisa Forte, Vera Frison, Giovanna Gregori, Cristina Lencioni, Gaetano Leto, S Mandica, Alberto Marangoni, Pasqualina Memoli, G Memoli, Carlo Negri, Laura Nollino, Andrea Perrelli, Sebastio Perrini, Flavia Prodam, Alberto Rebora, Daniela Sansone, Marcello Sciaraffia, Silvio Settembrini, G Sodo, F. Tassone, Valentina Todisco, Antonio Vetrano, Giacomo Accardo, Valeria Albanese, Irene Alemanno, Stefano Allasia, Rosario Alosa, Anna Altomari, Anna Maria Letizia Amato, E. Ambrosetti, Angela Angarano, Stefania Angotti, Roberto Anichini, Fabio Baccetti, M. Balbo, E Balestra, Sara Balzano, Maria Vittoria Barone, Walter Baronti, Veronica Basso, Guglielmo Beccuti, Iaele Maria Bellone, Alessandra Bertolotto, Michela Bettio, Cristina Bittante, Nadia Bonelli, Marzia Bongiovanni, Benedetta Maria Bonora, Barbara Bonsembiante, Laura Borgognoni, Daniela Bracaglia, Antonia Francesca Braione, Clementina Brancario, Sabrina Braucci, L. Briatore, Elisabetta Brun, Valeria Cambria, Elena Cantino, Paolo Capitanata, Sergio Cappello, Marina Caputo, Barbara Carabba, Alberto Carpenito, Marco Castellana, Anna Castrovilli, Donato Cataldo, Giuliana Cazzetta, Francesca Cecoli, Nino Cristiano Chilelli, Marco Cianciullo, Federica Coccia, Sara Colarusso, C Colella, Isabella Colletti, Sara Coluzzi, Marisa Conte, Marco Corigliano, Alessandra Cosma, Pantaleo Daniele, Maria D’aurizio, Alessandra De Bellis, Lorenzo De Candia, Giovanni Gennaro, E De Luca, Claudia De Natale, Giuseppina Simone, Raffaele De Simone, Andrea Del Buono, Vincenza Delmonte, Eleonora Devangelio, Nicolina Di Biase, Giuseppe Di Giovanni, Mariarosaria Di Palo, C. Divella, Mara Dolcino, Oreste Egione, Anna Farese, Saverio Fatone, Alessio Filippi, Daniela Fiore, Paolo Fiorentini, Rossana Fiori, Maria Rosa Fittipaldi, Giuseppina Floriddia, Luca Franco, Alessandra Fusco, Sergio Galdieri, Alessandra Gallo, Maria Alessandra Gardini, Francesca Garino, A Gatti, V Gatto, Carlotta Gauna, Luigi Gesuè, Anna Giacchini, Raffeale Giannettino, Debora Giannini, Filomena Gioia, Domenica Giuffrida, Umberto Goglia, Francesco Golia, Lucia Gottardo, Elena Gramaglia, Marco Grasso, Massimo Graziuso, Roberto Gualdiero, Rita Graziella Guarnieri, Nicolangelo Iazzetta, Marco Infante, Francesca Innelli, Angelantonio Iovino, Giovanni Izzo, Antonio Lampitella, Antonio Lanzilli, Emanuela Lapice, Anna Pia Lassandro, Adele Latina, Mario Laudato, Angelo Lauria Pantano, Paola Leporati, Filomena Lo Conte, Barbara Lucatello, T. Lucianer, B. Macerola, Valeria Maggi, Chiara Maggioli, Emilia Maglione, Francesco Manetti, Mariangela Manicone, A. Marcocci, V. Mariano, Elisa Marinazzo, Anna Maria Mariniello, Giuseppe Marrazzo, Emilia Martedì, Paolo Martini, M. Masin, Elisa Me, Marika Menduni, C Mesturino, Sabato Mignano, Nicola Milano, Monica Modugno, Eleonora Monti, Mary Mori, Elena Nazzari, Giuseppe Nunziata, Domenica Oliva, Marcello Orio, Antonio Palena, Pio Paraggio, Maria Divina Pascuzzo, Angela Peluso, Dorotea Peragine, Ettore Petraroli, Giuliana Petraroli, Giovanni Paolo Piccolo, Marco Piscopo, Roberta Poli, Stella Potenziani, Maria Chiara Quinto, Andrea Renzullo, G Rizzo, Rossella Romano, Ernesto Rossi, Ilaria Rubbo, Gilda Ruga, Angela Sabbatini, Francesca Santilli, Giovanna Saraceno, Patrizia Savino, Francesco Scalabrì, Carla Scarano, Maria Pia Scioti, Rachele Scotton, Antonello Selleri, Antonella Senesi, Marilena Sidoti, Maria Rosaria Sorrentino, Marco Strazzabosco, Daniela Strippoli, Miryam Talco, Anna Tedeschi, Annamaria Terracciano, G. Tirelli, Domenico Tricò, Salvatore Turco, Anna Turco, Livio Valente, Valeria Vallone, Carmela Vinci, D. T. Wolosinska
13Citations signalées — pas une note de qualité
8Institutions déclarées
1Pays d’affiliation déclarés
Résumé fourni par la source
INTRODUCTION: This study aimed to address therapeutic inertia in the management of type 2 diabetes (T2D) by investigating the potential of early treatment with oral semaglutide. METHODS: A cross-sectional survey was conducted between October 2021 and April 2022 among specialists treating individuals with T2D. A scientific committee designed a data collection form covering demographics, cardiovascular risk, glucose control metrics, ongoing therapies, and physician judgments on treatment appropriateness. Participants completed anonymous patient questionnaires reflecting routine clinical encounters. The preferred therapeutic regimen for each patient was also identified. RESULTS: The analysis was conducted on 4449 patients initiating oral semaglutide. The population had a relatively short disease duration (42% < 5 years), and a minority (15.6%) had a history of cardiovascular events. Importantly, oral semaglutide was started in subjects with various disease durations and background therapies. Notably, its initiation was accompanied by de-prescription of sulfonylureas, pioglitazone, DPP-4 inhibitors, and insulin. Choice of oral semaglutide was influenced by patient profiles and ongoing glucose-lowering regimens. Factors such as younger age, higher HbA1c, and ongoing SGLT-2 inhibitor therapy drove the choice of oral semaglutide with the aim of improving glycemic control. Projected glycemic effectiveness analysis revealed that oral semaglutide could potentially lead HbA1c to target in > 60% of patients, and more often than sitagliptin or empagliflozin. CONCLUSION: The study supports the potential of early implementation of oral semaglutide as a strategy to overcome therapeutic inertia and enhance T2D management.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care
- Date Crossref
- 18/10/2023
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins